Catheter Precision, Inc. (VTAK)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues-Product | 212 | - | - | - |
| Cost of revenues | 14 | 11 | - | - |
| Revenues | - | 143 | 96 | 93 |
| Cost of revenues | - | - | 10 | 16 |
| Gross profit | 198 | 132 | 86 | 77 |
| Research and development | - | - | 63 | 81 |
| Acquired in-process research and development | 1,848 | 119 | - | - |
| Selling, general and administrative | 2,881 | 3,485 | 2,882 | 2,713 |
| Research and development | 155 | 103 | - | - |
| Total operating expenses | 4,884 | 3,707 | 2,945 | 2,794 |
| Operating loss | -4,686 | -3,575 | -2,859 | -2,717 |
| Interest expense | - | 49 | - | - |
| Other expenses, net | -1 | - | -3 | -1 |
| Interest income | 3 | 18 | - | - |
| Interest expense-Service | 67 | - | - | - |
| Change in fair value of royalties payable due to related parties | -1,667 | -1,163 | - | - |
| Change in fair value of trading debt securities | 10 | - | - | - |
| Total other expenses, net | -1,722 | -1,194 | - | - |
| Loss from operations before income taxes | -6,408 | -4,769 | - | - |
| Income tax benefit | -950 | -724 | - | - |
| Net loss | -5,458 | - | - | - |
| Less net loss attributable to non-controlling interest | -349 | - | - | - |
| Change in fair value of royalties payable | - | - | -1,233 | -1,504 |
| Interest income | - | - | 7 | 2 |
| Interest expenses | - | - | 32 | - |
| Other operating income (expense), net | - | - | -1,261 | -1,503 |
| Net loss attributable to catheter precision, inc | -5,109 | -4,045 | -4,120 | -4,220 |
| Net income (loss) available to common stockholders, diluted | - | - | -4,120 | -4,220 |
| Basic & diluted average shares | - | - | - | 757,340 |
| Basic & diluted eps | - | - | -2.01 | -5.57 |
| Net loss per share attributable to catheter precision, inc., basic and diluted (in dollars per share) | -0.38 | -0.36 | - | - |
| Weighted-average common shares used in computing net loss per share, basic and diluted (in shares) | 13,336,088 | 11,283,929 | - | - |